The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...